ALX Oncology Holdings Inc (ALXO)
1.29
-0.04
(-3.01%)
USD |
NASDAQ |
Nov 15, 16:00
1.29
0.00 (0.00%)
After-Hours: 17:59
ALX Oncology Holdings Research and Development Expense (Quarterly): 26.47M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 26.47M |
| June 30, 2024 | 34.65M |
| March 31, 2024 | 31.72M |
| December 31, 2023 | 41.78M |
| September 30, 2023 | 45.77M |
| June 30, 2023 | 29.48M |
| March 31, 2023 | 24.76M |
| December 31, 2022 | 25.20M |
| September 30, 2022 | 29.38M |
| June 30, 2022 | 26.75M |
| March 31, 2022 | 17.07M |
| December 31, 2021 | 20.89M |
| Date | Value |
|---|---|
| September 30, 2021 | 18.21M |
| June 30, 2021 | 11.21M |
| March 31, 2021 | 9.849M |
| December 31, 2020 | 12.14M |
| September 30, 2020 | 5.328M |
| June 30, 2020 | 7.663M |
| March 31, 2020 | 3.828M |
| December 31, 2019 | 6.735M |
| September 30, 2019 | 2.21M |
| June 30, 2019 | 3.628M |
| March 31, 2019 | 3.733M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.828M
Minimum
Mar 2020
45.77M
Maximum
Sep 2023
21.45M
Average
22.83M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 184.90M |
| Neurocrine Biosciences Inc | 195.00M |
| Eton Pharmaceuticals Inc | 2.97M |
| Verve Therapeutics Inc | 49.94M |
| Immuneering Corp | 10.65M |